2542 indexable Biopharma Outsourcing companies headquartered in United States, ranked by total equity funding and recent funding momentum. Combined disclosed equity funding of $20.3B across 483 funded companies, including 1 unicorn.
| # | Company | Funding | Valuation | Stage | Latest round | Employees | Founded | Momentum |
|---|---|---|---|---|---|---|---|---|
| 1 |
Resilience
Provider of supply chain services for biopharma sector |
$2B | — | Series D | Venture Debt Oct 2025 | 1,767 | 1995 | ↑ Active |
| 2 |
Alloy Therapeutics
Provider of drug discovery services |
$117M | — | Series E | Series E Mar 2026 | 130 | 2017 | ↑ Active |
| 3 |
Kardigan
Biotech company developing personalized medicines for cardiovascular diseases |
$554M | — | Series B | Series B Oct 2025 | — | 2023 | ↑ Active |
| 4 |
SpectronRx
Provider of therapeutic and diagnostic isotope solutions |
$85M | — | Series C | Series C Apr 2026 | 93 | 2004 | ↑ Active |
| 5 |
Ember LifeSciences
Provider of cold chain logistics services for biopharma sector |
$37.4M | — | Series A | Series A May 2026 | — | 2022 | ↑ Active |
| 6 |
Kashiv BioSciences
Developer of biosimilar medicines |
$222.3M | — | Acquired | Conventional Debt Dec 2025 | 235 | 2010 | ↑ Active |
| 7 |
Tenpoint Therapeutics
Developer of engineered cell-based therapeutics to restore vision |
$70M | — | Series B | Series B Jan 2026 | 14 | 2020 | ↑ Active |
| 8 |
InduPro
Provides science to manipulate protein interactions and explore new possibilities for treating patients |
$85M | — | Series A | Series A Dec 2025 | 34 | 2022 | ↑ Active |
| 9 |
Oryon
Developer of autologous neuron replacement medicines for neurodegenerative disorders |
$21M | — | Series A | Series A Mar 2026 | — | 2020 | ↑ Active |
| 10 |
Hyku Biosciences
Covalent medicines platform for expanding the boundaries of drug discovery |
$56M | — | Seed | Seed Dec 2025 | — | 2023 | ↑ Active |
| 11 |
Superluminal Medicines
Generative biological and chemical company focused on drug discovery |
$153M | — | Series A | Series A Aug 2025 | — | 2022 | ↑ Active |
| 12 |
PCI
Provider of clinical & commercial supply chain and packaging solutions |
$205M | — | Late Stage | PE Jul 2025 | 4,300 | 1997 | ↑ Active |
| 13 |
Surrozen
Pioneering targeted regenerative antibodies to repair tissue and restore organ function |
$326M | — | Public | Post IPO Mar 2025 | 80 | 2016 | ↑ Active |
| 14 |
GBI
Provider of contract based drug manufacturing, regulatory support, and quality assurance services |
$25.7M | — | Early Stage | Unattributed Dec 2025 | 62 | 1992 | ↑ Active |
| 15 |
Acclinate
Provider of clinical trial services to biopharma sector |
$12M | — | Series A | Series A Feb 2026 | 33 | 2020 | ↑ Active |
| 16 |
Caidya
CRO focused on clinical development for phases II & III clinical trials and regulatory affair services |
$373M | — | Series C | PE Jan 2025 | 351 | 2003 | ↑ Active |
| 17 |
Rho
Full and functional service CRO offering clinical development services |
$67.5M | — | Funding Raised | Grant (prize money) May 2025 | 859 | 1984 | ↑ Active |
| 18 |
Tri-Pac
Offers contract manufacturing, filling and packaging services |
$5.6M | — | Seed | Seed Feb 2026 | 122 | 2009 | ↑ Active |
| 19 |
XDemics
CDMO focused on manufacturing cell & viral based therapeutics |
$14.8M | — | Series B | Series B Oct 2025 | — | 2017 | ↑ Active |
| 20 |
Lifecore
Sterile injectable CDMO and sodium hyaluronate producer, advancing pharmaceutical possibilities |
$268.7M | — | Public | Post IPO Oct 2024 | 459 | 1965 | ↑ Active |
| 21 |
BlueWhale
Provider of cell & gene therapies development and research services |
$18M | — | Series A | Series A Oct 2025 | — | 2022 | ↑ Active |
| 22 |
Phlow
CDMO focused on manufacturing of API products for biopharma sector |
$85.2M | — | Series C | Series C Jan 2025 | 55 | 2020 | ↑ Active |
| 23 |
Javara Research
Integrating clinical research at the point of care for better outcomes |
$40M | — | Series B | Series B May 2025 | 233 | 2018 | ↑ Active |
| 24 |
Wheeler Bio
Provider of drug research and analytical development services for multiple therapeutic areas |
$68.2M | — | Series A | Series A Mar 2025 | 42 | 2020 | ↑ Active |
| 25 |
Kincell Bio
Provider of clinical cell therapy development & manufacturing and consulting services |
$36M | $66M as of 2023 |
Series A | Series A May 2025 | — | 2023 | ↑ Active |
| 26 |
Lifordi
Biotechnology company developing treatments for autoimmune and inflammatory disorders using antibody-drug conjugates |
$5.9M | — | Seed | Seed Nov 2025 | — | 2023 | ↑ Active |
| 27 |
revalia bio
Provider of contract based drugs development services for biopharma sector |
$12.3M | — | Seed | Seed Sep 2025 | 3 | 2021 | ↑ Active |
| 28 |
Trial Library
Provider of clinical trial for drug research & development services |
$5M | — | Series A | Series A Dec 2025 | 9 | 2018 | ↑ Active |
| 29 |
Clinical Trial Research
Network of research sites providing clinical trial management services |
$5M | — | Late Stage | PE Nov 2025 | — | 2025 | ↑ Active |
| 30 |
CubeWorks
Provider of millimeter-scale wireless sensors |
$1.1M | — | Series A | Series A Feb 2026 | 14 | 2013 | ↑ Active |
| 31 |
US Pharmatech
Producer of nutraceuticals and dietary supplements for global brands |
$3.4M | — | Funding Raised | Conventional Debt Dec 2025 | — | 2017 | ↑ Active |
| 32 |
Indapta
Limited information available |
$72.8M | — | Series A | Series A Dec 2024 | 14 | 2016 | ↑ Active |
| 33 |
Exela Pharma
Manufacturer of sterile injectable pharmaceutical products and CDMO services |
$6.7M | — | Series B | Grant (prize money) Sep 2025 | 205 | 2005 | ↑ Active |
| 34 |
Liberation Labs
CRO focused on providing fermentation products manufacturing and commercialisation services |
$36M | — | Series C | Series C Jan 2025 | 13 | 2022 | ↑ Active |
| 35 |
DNA Nanobots
Biotech company that uses nanotechnology to deliver targeted chemotherapy, vaccines, and gene therapy |
$3.5M | — | Seed | Seed Dec 2025 | — | 2021 | ↑ Active |
| 36 |
TissueVision
Innovating whole tissue imaging and analysis solutions for life-saving therapies |
$13.4M | — | Funding Raised | Grant (prize money) May 2025 | 17 | 2005 | ↑ Active |
| 37 |
GSSHealth
Provider of data management, logistics and training services |
$18.2M | — | Funding Raised | Grant (prize money) Apr 2025 | — | 2009 | ↑ Active |
| 38 |
Dash Bio
Provider of automated bioanalysis platform for accelerated clinical drug development |
$17.5M | — | Series A | Series A Jun 2025 | — | 2024 | ↑ Active |
| 39 |
Abbratech
CRO focused on providing antibody discovery & development services |
$8.5M | — | Series A | Grant (prize money) Jul 2025 | 9 | 2020 | ↑ Active |
| 40 |
Cayman Chem
Develops bioreagents and offers preclinical services |
$8.6M | — | Funding Raised | Grant (prize money) Jun 2025 | 309 | 1980 | ↑ Active |
| 41 |
PPD
CRO providing diversified clinical development services |
$1B | — | Acquired | Grant (prize money) Oct 2023 | 1,530 | 1985 | — |
| 42 |
Inceptor
CDMO offering services for cell and gene therapy products |
$37.7M | — | Series A | Series A Jan 2025 | 69 | 2020 | ↑ Active |
| 43 |
Simulations Plus
Developer of modeling and simulation software and consulting services provider |
$8M | — | Public | Grant (prize money) Jun 2025 | 197 | 1996 | ↑ Active |
| 44 |
Afaxys
Affordable sexual and reproductive healthcare access for all, mission-driven |
$8M | — | Seed | Grant (prize money) Aug 2025 | 39 | 2008 | ↑ Active |
| 45 |
Fauna Bio
Healthcare association involved in animal genomics |
$13.1M | — | Seed | Seed Apr 2025 | 15 | 2018 | ↑ Active |
| 46 |
Manifold Bio
Developer of tissue-targeted therapeutics using in vivo screening and AI design |
$45.4M | — | Series A | Series A Nov 2024 | 22 | 2018 | ↑ Active |
| 47 |
Tharimmune
Clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic conditions |
$2.1M | — | Public | Post IPO Nov 2025 | 1 | 2023 | ↑ Active |
| 48 |
Protein Dynamic Solutions
Transforming protein analytics for better biotherapeutics, enhancing regulatory compliance |
$4.1M | — | Seed | Seed Aug 2025 | 9 | 2015 | ↑ Active |
| 49 |
BioMADE
Provider of clinical trial research site services for biopharma sector |
$4.8M | — | Funding Raised | Grant (prize money) Aug 2025 | 71 | 2020 | ↑ Active |
| 50 |
New Iridium
Manufacturer of phenoxazine and dihydrophenazine |
$6.1M | — | Seed | Seed Jun 2025 | 11 | 2016 | ↑ Active |
Provider of supply chain services for biopharma sector
Provider of drug discovery services
Biotech company developing personalized medicines for cardiovascular diseases. It is a biotechnology company focused on developing precision medicines for cardiovascular disease. The company aims to modernize cardiovascular drug development with a late-stage portfolio of personalized medicines.
SpectronRx is a provider of therapeutic and diagnostic isotope solutions. It provides radionuclides and custom theranostic contract manufacturing like monoclonal antibody labelling, peptides, radiolabeling of molecules and chemical entities, and aptamers.
Provider of cold chain logistics services for biopharma sector
Developer of biosimilar medicines. It is an integrated biopharmaceutical company with capabilities in R&D, clinical, manufacturing, regulatory, and intellectual property.
Developer of engineered cell-based therapeutics to restore vision. The company is advancing cell-based therapies and in vivo reprogramming to restore vision loss caused by the deterioration of functional tissue for people with degenerative ocular diseases.
InduPro is a biotechnology company that focuses on bringing proteins on the cell surface closer together, manipulating their interactions to open up new possibilities for treating various conditions. They have a multidisciplinary team with backgrounds in pharma, academia, and biotech, and they are dedicated to impacting patients' lives through innovative drug development.
Developer of autologous neuron replacement medicines for neurodegenerative disorders. The company focuses on developing medicines to replace lost neurons. It aims to restore function for Parkinson’s disease and other neurodegenerative disorders.
It has launched with $56 million in funding to advance its covalent medicines platform, which targets histidine, tyrosine, and lysine binding pockets in disease-causing proteins. The company aims to expand the boundaries of drug discovery with its innovative covalent platform.
Superluminal Medicines Inc. is a biotechnology research company based in Boston, Massachusetts. They specialize in generative biological and chemical solutions for drug discovery programs. The company recently launched with a $33 million seed round to fuel its drug discovery engine and pipeline of small molecule therapeutics.
Provider of clinical & commercial supply chain and packaging solutions
Rankings are computed by Radar (Fliar BI) from the Radar company master and are updated periodically. Funding and momentum scores use disclosed equity-funding data only. Figures may lag private rounds. Last updated 2026-06-16.
